AtCor Medical announced the publication of the Novartis Pharmaceuticals Corporation's PARAMETER study1 in the influential journal Hypertension. The purpose of this study was to determine the effectiveness of its new drug in reducing central aortic systolic pressure (CASP) in elderly patients, which was the primary end point and measured using SphygmoCor XCEL. The randomised controlled trial examined 454 multi-ethnic elderly patients with systolic hypertension (high blood pressure) at 48 sites in 12 countries and determined that the new drug compound, sacubitril/valsartan was more effective than the currently used drug, olmesartan, in reducing CASP and central aortic pulse pressure (CAPP) within the trial period (p=0.01).